Coherus Oncology Inc. Common Stock (CHRS)
Stock · NASDAQ · Health Care
$1.41as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Resistance level
$1.62
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About CHRS
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoc…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 144
- Website
- www.coherus.com/
Fundamentals
- 1-day range
- $1.41$1.48
- Market cap
- $222.12M
- P/E (trailing)
- —
- P/E (forward)
- -2.32
- EPS (trailing)
- $-1.03
- Dividend yield
- —
- Beta
- 0.97
- Avg. volume
- 1.01M
52-week range
$1.09$2.62
Next earnings: November 5, 2026 · EPS estimate $-0.21confirmed
How Coherus Oncology Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 9, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Buy 85%
Hold 15%
Sell 0%
1-year price forecast
High
$10
+609.2%
Median
$8.5
+502.8%
Low
$4
+183.7%
Coherus Oncology Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CHRSCoherus Oncology Inc. Common Stock$1.41▼ 3.42%Market cap $222.12MP/E —$1.09$2.62
- TARAProtara Therapeutics Inc. Common Stock$3.82▼ 4.26%Market cap $223.13MP/E —$3.02$7.82
- SRZNSurrozen Inc. Common Stock$22.42▼ 6.62%Market cap $252.87MP/E —$10.73$35
- ARMPArmata Pharmaceuticals Inc. Common Stock$5.24▼ 3.50%Market cap $185.39MP/E —$2.4$16.34
- EDITEditas Medicine Inc. Common Stock$3.15▼ 4.55%Market cap $259.45MP/E —$1.66$4.54
- VYGRVoyager Therapeutics Inc. Common Stock$3.54▲ 2.17%Market cap $181.26MP/E —$2.94$5.55
- AVXLAnavex Life Sciences Corp. Common Stock$2.98▼ 4.79%Market cap $273.38MP/E —$2.26$10.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CHRS Coherus Oncology Inc. Common Stock | $222.12M | — | $1.41 | ▼ 3.42% | $1.09$2.62 |
| TARA Protara Therapeutics Inc. Common Stock | $223.13M | — | $3.82 | ▼ 4.26% | $3.02$7.82 |
| SRZN Surrozen Inc. Common Stock | $252.87M | — | $22.42 | ▼ 6.62% | $10.73$35 |
| ARMP Armata Pharmaceuticals Inc. Common Stock | $185.39M | — | $5.24 | ▼ 3.50% | $2.4$16.34 |
| EDIT Editas Medicine Inc. Common Stock | $259.45M | — | $3.15 | ▼ 4.55% | $1.66$4.54 |
| VYGR Voyager Therapeutics Inc. Common Stock | $181.26M | — | $3.54 | ▲ 2.17% | $2.94$5.55 |
| AVXL Anavex Life Sciences Corp. Common Stock | $273.38M | — | $2.98 | ▼ 4.79% | $2.26$10.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug DevelopmentSeekingAlpha · 8/19/2026
- Coherus Oncology Reveals Special Dividend of Biosimilar Contingent Value Rights; Company Intends To Immediately Commence A Sale Process For The Legacy Biosim AssetsBenzinga · 8/17/2026
- Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10Benzinga · 8/7/2026
- Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call TranscriptSeekingAlpha · 8/7/2026
- Coherus Oncology, Inc. Q2 2026 Earnings Call SummaryYahoo · 8/6/2026
- Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ...Yahoo · 8/6/2026
- Coherus Oncology Q2 Earnings Call HighlightsYahoo · 8/6/2026
- Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue EstimatesYahoo · 8/5/2026
Insider Activity
Insider Actions →Acquired
660.0K
Disposed
0
- Ali J. Satvat · June 5, 2026 · Grant60.0K
- Ali J. Satvat · June 5, 2026 · Grant30.0K
- Rita A. Karachun · June 5, 2026 · Grant60.0K
- Rita A. Karachun · June 5, 2026 · Grant30.0K
- Lee Nisley Newcomer · June 5, 2026 · Grant60.0K
- Lee Nisley Newcomer · June 5, 2026 · Grant30.0K
- Michael Lee Ryan · June 5, 2026 · Grant60.0K
- Michael Lee Ryan · June 5, 2026 · Grant30.0K
- Jill O'Donnell-Tormey · June 5, 2026 · Grant60.0K
- Jill O'Donnell-Tormey · June 5, 2026 · Grant30.0K
- Charles W. Newton · June 5, 2026 · Grant60.0K
- Charles W. Newton · June 5, 2026 · Grant30.0K
- Mats Wahlstrom · June 5, 2026 · Grant60.0K
- Mats Wahlstrom · June 5, 2026 · Grant30.0K
- Bryan J. McMichael · May 29, 2026 · Grant30.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 57.77M
- Total value held
- $93.22M
- Institutional holders
- 152
Top holders this quarter
- Unknown10.37M
- Unknown5.45M
- Unknown3.43M
- Unknown3.12M
- Unknown3.04M
- Unknown2.33M
- Unknown2.30M
- Unknown2.25M
- Unknown2.10M
- Unknown1.93M
See the full, filterable feed with live charts on the MarketWall dashboard.